Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $749000.0.

  • Taysha Gene Therapies' Other Accumulated Expenses fell 1449.77% to $749000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $749000.0, marking a year-over-year decrease of 1449.77%. This contributed to the annual value of $752000.0 for FY2024, which is 401.11% up from last year.
  • Taysha Gene Therapies' Other Accumulated Expenses amounted to $749000.0 in Q3 2025, which was down 1449.77% from $800000.0 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other Accumulated Expenses ranged from a high of $1.6 million in Q1 2022 and a low of $650000.0 during Q4 2022
  • Moreover, its 4-year median value for Other Accumulated Expenses was $777000.0 (2024), whereas its average is $907533.3.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 5689.87% in 2023, then skyrocketed by 2863.44% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Other Accumulated Expenses (Quarter) stood at $650000.0 in 2022, then rose by 11.23% to $723000.0 in 2023, then increased by 4.01% to $752000.0 in 2024, then decreased by 0.4% to $749000.0 in 2025.
  • Its last three reported values are $749000.0 in Q3 2025, $800000.0 for Q2 2025, and $806000.0 during Q1 2025.